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Increasing evidence has shown that the stem-loop (SL) structures in the NS5B coding region of hepatitis C virus (HCV) function as
cis-replicating elements that are indispensable for viral replication. We have investigated whether small RNA molecules analogous to the SL
structures could inhibit HCV replication. Reporter assays showed that both in vitro transcribed and pol III-directed transcripts corresponding
to 5BSL3.1 and 5BSL3.2 efficiently inhibited HCV replicon-encoded luciferase expression. Mutagenesis studies revealed that mutation in
5BSL3.2 which debilitated its binding to NS5B also abolished the ability of 5BSL3.2 RNA to inhibit HCV replication, suggesting that SL
RNA inhibits HCV by sequestering the replication complex. Further, adenoviral-mediated expression of the SL RNAs potently blocked the
replication of HCV replicon in Huh-7 cells. Importantly, SL RNAs derived from HCV 2a, an evolutionarily distant genotype, were also
shown to suppress the replication of HCV 1b replicon in spite of the genetic heterogeneity between the SL elements of the two viruses,
implying the potential of SL RNA-based approach to inhibit a wide range of HCV isolates. These results suggest that SL RNA decoys may
prove to be useful in the treatment of hepatitis C, which may be advantageous over other sequence-specific gene therapy modalities (such as
antisense RNA and siRNA) in preventing the escape of genetic variants.
D 2005 Elsevier Inc. All rights reserved.Keywords: RNA decoy; Hepatitis C virus; Stem-loop; Gene therapyIntroduction
Infection with hepatitis C virus (HCV), the main
causative agent for non-A, non-B hepatitis, is a serious
worldwide health problem. It is estimated that more than
200 million individuals are infected with HCV, and many of
them are at a high risk for developing liver cirrhosis and
hepatocellular carcinoma (Alter, 1997). Current therapeutic
regimens using interferon-a, whether alone or in combina-
tion with ribavirin, have limited efficacy (McHutchison,
2002). Although small inhibitory molecules targeting serine0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.003
* Corresponding author. Fax: +81 6 6964 2706.
E-mail address: j-zhang@fuso-pharm.co.jp (J. Zhang).protease, helicase, or RNA-dependent RNA polymerase
(RdRp) are in development, one unavoidable problem is
selection of resistant mutants conferred by single or multiple
mutations due to the error-prone nature of RdRp (Linden-
bach and Rice, 2003; Lu et al., 2004; Nguyen et al., 2003).
The potential of using small RNA molecules as
therapeutic agents has been extensively explored, antisense
RNA, ribozyme, and more recently siRNA have been
demonstrated to be highly efficient in inhibiting a number
of pathogenic viruses, including HCV (Gitlin et al., 2002;
Jacque et al., 2002; Randall et al., 2003). However, because
of the highly sequence-specific property intrinsic in these
approaches, the antiviral efficacy is largely limited by
emergence of escape variants due to high mutation rates of
viruses (Gitlin et al., 2002; Wilson and Richardson, 2005).05) 276 – 285
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tion of RNA viruses is to overexpress small and structured
viral RNA elements, which function as decoys to compete
with the corresponding sequences in viral RNA for viral
regulatory proteins binding, thereby inhibiting essential
viral gene expression. It has been reported that over-
expression of trans-acting response element (TAR) (Sullen-
ger et al., 1990) and Rev response element (RRE) RNAs
(Lee et al., 1992) rendered cells resistant to HIV replication
by preventing the interaction of Tat and Rev proteins with
the viral RNA.
The replication of HCV requires a membrane-associated
replication complex of viral and cellular proteins as well as a
viral RNA template containing cis-acting replication ele-
ments (CRE). In addition to RNA signals reside in the 5V
and 3V untranslated region (UTR) of HCV RNA, the highly
conserved and stable stem-loop (SL) structures in the C-
terminal NS5B coding region have also been demonstrated
to contain CREs that are indispensable for HCV replication
(Friebe et al., 2005; Lee et al., 2004; You et al., 2004). The
function of cis-acting RNA elements is frequently mediated
by binding of viral or cellular proteins. In fact, recent studies
have provided evidence showing a correlation between the
RdRp-binding ability and replication competency of the
5BSL mutants (Lee et al., 2004), suggesting that the
replication complex containing RdRp is likely to exert its
function by interacting with the 5BSL domain(s). If this is
the case, overexpression of the RNA species encoding such
SL structure(s) could act as decoys to sequester viral and/or
host cell factors and prevent their binding to corresponding
sequences in the viral RNA, thereby inhibiting HCV
infection. Unlike the fore-mentioned sequence-specific
antiviral molecules, such a strategy targeting protein–viral
RNA interaction should be minimally affected by the
genetic heterogeneity of HCV isolates.
In this study, we investigated the therapeutic feasibility of
small RNA molecules encoding the defined SL structures in
NS5B region. Our results demonstrate that adenoviral-
delivered small RNA molecules corresponding to 5BSL3.1
and 5BSL3.2 efficiently inhibit HCV RNA replication in
Huh-7 cells that stably replicate the subgenomic replicon.Results
Down-regulation of HCV replication by in vitro transcribed
RNA corresponding to 5BSL3.1 and 5BSL3.2
By using various computational analysis and phyloge-
netic comparisons, several different groups have analyzed
the HCV genome for the presence of stable and highly
conserved RNA secondary structures in the NS5B coding
region (Hofacker et al., 1998; Tuplin et al., 2002), and
moreover the predicted SL structures were recently demon-
strated to contain CRE that is crucial for replication of
subgenomic replicon in cultured cells. To explore whetherthe small RNA species encoding the SL sequences can act
as therapeutic decoys, RNAs corresponding to the defined
SL structures (5BSL3.1, 5BSL3.2, and 5BSL3.3), VR-U/
UC containing variable region plus polyU/UC tract, and X-
tail were transcribed in vitro, and transfected into Huh-7
cells together with the replicon RNA in vitro transcribed
from pLMH14 (Murata et al., 2005), which contains the 5V
UTR, the first 36 nucleotides of the core region fused
directly with the firefly luciferase (Fluc) reporter gene, the
IRES element from encephalomyocarditis virus (EMCV)
that directs translation of the HCV proteins from NS3 to
NS5B and the 3V UTR of HCV RNA. Additionally, the
small RNA encoding the sequence from nt 9129 to 9189
(S9129), which encompasses a structure predicted by Tuplin
et al. (referred to as SL8926 in Tuplin et al., 2002) but
not identified by You et al. (2004), was also included.
RNA transcribed from a replication-deficient construct
pLMH14GHD carrying an inactive GHD motif in RdRp
served as a negative control. The replicon-encoded lucifer-
ase expression, which was used as a read out of HCV RNA
levels, was assayed at 3 and 72 h posttransfection. The
luciferase levels at 3 h posttransfection were used to correct
transfection efficiency. Transfection with RNA encoding
5BSL3.1 or 5BSL3.2 significantly inhibited the luciferase
expression from replicon, causing a reduction in relative
Fluc activity to 25.5% and 20.7%, respectively, compared
with the control in which SL RNA was absent (Fig. 1B).
There was no significant inhibition of Fluc activity in cells
transfected with the corresponding amount RNA of S9129,
5BSL3.3, or VR-U/UC, whereas X-tail RNA caused a
marginal inhibition (75.3%) of Fluc activity. This result
provides first evidence supporting our hypothesis that the
replication complex can be functionally inactivated by
sequestering them from the HCV RNA by virtue of small
RNAs encoding SL structures such as 5BSL3.1 and
5BSL3.2.
Significantly, the small RNAs corresponding to the
5BSL3.1 and 5BSL3.2 domains of HCV 2a, which differ
from those in HCV 1b in 13 out of 44 nucleotides and 6 out
of 48 nucleotides (Fig. 1A), also inhibited the replication of
replicon RNA from pLMH14 (HCV 1b) although the
inhibition extent was less (48.3% and 37.1%, respectively).
These data indicate that HCV 2a-derived SL RNAs could
cross-interact with the RdRp of HCV 1b despite the genetic
diversity between the SL elements of the two viruses,
suggesting the potential of SL RNA-based approach to
inhibit a wide range of HCV isolates.
Inhibition of HCV replication by pol III-directed SL RNAs
In gene inhibition protocol with small RNA structures,
RNA polymerase III (pol III)-based transcription is desirable
because pol III promoter is highly productive and capable of
generating complex RNA structures with high integrity. For
this reason, we next cloned the coding sequence for the SL
structure into an expression vector demonstrated to express
Fig. 1. Effects of in vitro transcribed RNA on HCV replicon-encoded luciferase expression. (A) The sequence and proposed secondary structure in the
C-terminal NS5B coding region of HCV 1b replicon. The nucleotides in HCV 2a that differ from those in HCV 1b are indicated. The SL structure prediction
and designation are from You et al. (2004) and Friebe et al. (2005). VR-U/UC, variable region plus U/UC tract. (B) Huh-7 cells were transfected with non-
replicating replicon RNA (LMH14GHD), or replicating replicon RNA (LMH14) together with indicated in vitro transcribed RNA. Luciferase activities were
measured at 3 h and 72 h posttransfection. Luciferase activities at 3 h were used to normalize the transfection efficiency. Relative luciferase activity at 72 h in
cells transfected with control (scrambled) RNAwas defined as 100%, and those from other transfectants are expressed as relative percentage. The columns and
bars represent the means and standard deviations of three independent triplicate transfections. S9129, RNA encoding the sequence from nt 9129 to 9189.
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human U6 promoter (Zhang et al., 2004), creating pShut-
tleSL vectors. Huh-7 cells were transfected with each SL
expressing vector, XbaI-linearized pLMH14, pAM8-1
plasmid expressing T7 RNA polymerase (Zhang et al.,
1999), and pRL-TK (Promega) vector. Instead of in vitro
transcribed replicon RNA, we used here a linear DNA
replicon template combined with T7 polymerase expressing
plasmid because it elicited more efficient replication of
HCV replicon in our preliminary study. Transfected cells
were harvested and Fluc activities were measured after 24,
48, 72, 96, and 120 h. The Renilla luciferase (Rluc) activityfrom cotransfected pRL-TK vector was simultaneously
measured at 24 h posttransfection to normalize the trans-
fection efficiency. Fig. 2 shows the time course of the
replication level of HCV RNA, as indicated by luciferase
activity. Huh-7 cells transfected with pShuttle empty vector
support the replication of replicon RNA from pLMH14, as
evidenced by a constant or even elevated level of Fluc
activity after 72 h. Because the RdRp encoded in
replication-deficient replicon (pLMH14GHD) is dysfunc-
tional, luciferase expression from pLMH14GHD would
depend on the transiently expressed T7 RNA polymerase
and decrease with the diminution of T7 polymerase.
Fig. 2. Inhibition of HCV replication by pol III-directed 5BSL3.1- and
5BSL3.2-containing transcripts. Huh-7 cells were transfected with line-
arized pLMH14GHD (replication-deficient), or pLMH14 (replication-
competent), pAM8-1 plasmid expressing T7 RNA polymerase, and
pShuttle empty or pShuttleSL vector. Relative luciferase activities in the
lysates were determined at the indicated time points. The data represent the
means of two independent experiments.
J. Zhang et al. / Virology 342 (2005) 276–285 279As expected, the Fluc expression from pLMH14GHD
decreased with time and reached a background level at 72
h after transfection, although a comparable Fluc activity was
observed at 24 h posttransfection. Compared with the cells
transfected with pShuttle empty vector, diminished lucifer-
ase expression was detected in cells transfected with
pShuttleSL3.1 and pShuttleSL3.2, especially at the time
points after 72 h posttransfection. In agreement with the
reporter assay using in vitro transcribed RNA, luciferase
expression was not significantly changed in the cells
transfected with pShuttleSL3.3.
Because translation of Fluc in pLMH14 is under the
control of HCV IRES, and synthesis of the NS proteins is
directed by EMCV IRES, thus down-regulation of HCV
IRES- or EMCV IRES-mediated translation may also lead
to a reduction in replicon-encoded Fluc expression. To
investigate whether the inhibitory effect of SL RNA on Fluc
expression was due to its influence on HCV IRES- or
EMCV IRES-dependent translation, we performed reporter
assays with pHCVRLNS5B and pEMCVRLNS5B, in
which the expression of Rluc gene is directed by HCV
IRES (nucleotides 1–377) and EMCV IRES (Zhang et al.,
2002) identical to that inserted in the replicon, respectively.
As a positive control, we used SL e + f element of HCV
IRES domain III, which was reported to inhibit HCV IRES-
mediated translation by interacting with the ribosomal S5
protein and preventing the recruitment of the 40S ribosomal
unit (Ray and Das, 2004). While trans-expression of the
SL e + f RNA inhibited HCV IRES-dependent Rlucexpression, neither HCV IRES- nor EMCV IRES-directed
Rluc expression was significantly affected by overexpres-
sion of SL RNAs, indicating that the suppressive activity of
5BSL3.1 and 5BSL3.2 was specific to HCV replication
rather than to HCV IRES- or EMCV IRES-mediated
translation (Figs. 3A and B). Additionally, to rule out the
possibility that the SL RNA-mediated HCV inhibition was a
consequence of RNAi effect, reporter assay with
pNS5BRL, which contains the NS5B coding sequence
encompassing the SL structures studied here fused in frame
directly to the N-terminal of Rluc gene, was also conducted
as described above. Although a significant reduction in
Rluc activity was observed in cells transfected with
pShuttlesiRL expressing siRNA against Rluc gene, Rluc
expression from pNS5BRL was not inhibited by cotrans-
fection with each pShuttleSL, indicating that the inhibitory
activity of small SL RNA was not due to RNAi effect (Fig.
3C). Taken together, these observations provide further
evidence supporting our hypothesis that small RNAs
encoding SL structures such as 5BSL3.1 and 5BSL3.2
can inhibit HCV replication by competing with HCV RNA
for replication complex binding.
Correlation between NS5B-binding ability and anti-HCV
activity of mutant 5BSL3.2
To address the issue whether, as hypothesized, SL RNAs
inhibit HCV replication by sequestering replication com-
plex, we analyzed the effects of sequence alterations on the
function of corresponding SL RNA decoys. For this
purpose, two mutant 5BSL3.2 RNAs were in vitro tran-
scribed and subjected to reporter assay and gel shift assay in
parallel. As shown in Fig. 4A, 5BSL3.2m-1 contains two A
to U substitutions in the upper loop region, which would
disrupt the presumed kissing-loop interaction with SL2 in
the X-tail; 5BSL3.2m-2 was generated by deletion of 3
nucleotides (CGC) in the internal bulge. Fig. 4B shows that
the ability of 5BSL3.2 to inhibit replicon-encoded luciferase
expression was not significantly affected by a double point
mutation in the upper loop (5BSL3.2m-1). However, a CGC
trinucleotide deletion in the bulge (5BSL3.2m-2) abolished
the ability of the corresponding RNA to inhibit the
luciferase expression from HCV replicon. Gel shift assay
was carried out with cytoplasmic extract from HepG2 cells
expressing myc-tagged NS5B protein and labeled NS5B (nt
9067–9374) RNA. The result showed that RNA–protein
complexes of slower electrophoretic mobility were formed
in the binding mixture, which were supershifted by mAb
(9E10) against the myc-epitope tag (Fig. 4C, lane 3). The
formation of RNA–protein complex was significantly
inhibited by an excess of unlabeled homologous NS5B
RNA, indicating the specificity of the observed RNA–
protein binding. The binding of labeled NS5B RNA to myc-
tagged NS5B protein was also competed away by the
presence of an excess of unlabeled wild-type 5BSL3.2 or
5BSL3.2m-1, albeit to less extent. In contrast, an increasing
Fig. 3. Effects of SL RNAs on HCV IRES- (A), or EMCV IRES-dependent translation (B). Huh-7 cells were transfected with pHCVRLNS5B (A) or
pEMCVRLNS5B (B), which contains T7 promoter, IRES element from HCV or EMCV, and Renilla luciferase (Rluc) gene followed by NS5B coding
sequence, pAM8-1, and pShuttle empty or pShuttleSL vector. (C) The antiviral activity of SL RNAs was not due to RNAi effect. Huh-7 cells were transfected
with pNS5BRL, which contains NS5B coding sequence fused in frame with the Rluc gene between SV 40 promoter and SV 40 poly (A), and pShuttle empty,
pShuttleSL, or pShuttlesiRL vector expressing siRNA against Rluc gene. Relative Renilla luciferase activities in the lysates were determined as described for
Fig. 1. The columns and bars represent the means and standard deviations of two separate triplicate transfections.
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bulge, which was shown to abolish the ability of 5BSL3.2 to
inhibit HCV replication, did not attenuate the formation of
the complexes between the labeled NS5B RNA and myc-
tagged NS5B protein in the lysate. Taken together, these
results support our hypothesis that inhibition of HCV in
cells expressing SL RNA decoys occurs by interfering with
the interaction between RdRp containing replicase complex
and HCV RNA.
Potent inhibition of HCV replication by
adenoviral-mediated expression of SL RNAs
To further investigate the therapeutic utility of small SL
RNA in combating HCV infection, we cloned each SL RNAexpression cassette into recombinant adenovirus vector, and
the effect of adenoviral-delivered SL RNA expression on
HCV RNA replication was investigated by quantification of
HCV replicon RNA levels and viable cell count in G418
selection assay. Huh-NNRZ cells, which autonomously
replicate HCV subgenomic replicon carrying neomycin
resistant gene, were transduced with each SL RNA
expressing adenovirus at the multiplicity of infection
(MOI) of 50, 25, and 10 and maintained for a total of 5
days in the absence of G418 selection. Cells were then
harvested and total RNAs were subjected to real-time RT-
PCR. As shown in Fig. 5A, transduction with AdSL3.1 and
AdSL3.2 resulted in a substantial and dose-dependent
reduction in replicon RNA copies, reducing HCV transcripts
by 35- and 38-fold, respectively, at the MOI of 50. HCV
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with AdSL3.3, even at the MOI of 50, fully consistent with
the results from reporter assay using HCV replicon carrying
the luciferase gene.The antiviral effect of AdSL3.1 and AdSL3.2 was further
confirmed in G418 selection assay. The G418 resistance of
Huh-NNRZ cells is conferred by persistent expression of
neomycin phosphotransferase from replicating HCV RNAs,
thus the ability of Huh-NNRZ cells to grow in G418-
containing medium can be taken as an indirect measure of
HCV replication. In the absence of G418, viability of the
cells transduced with each AdSLRNA was comparable to
that of mock-infected cells, indicating that overexpression of
SL RNA in Huh-NNRZ cells had no adverse effect on cell
growth (see discussion). After a 10-day exposure to G418,
cells transduced with AdSL3.1 and AdSL3.2 showed a
marked and dose-dependent reduction in viable cell count,
decreasing viable cells by 18- and 20-fold, respectively, at
the MOI of 50 (Fig. 5B). Again, no significant effect on
cell growth in the presence of G418 was observed by
transduction with AdSL3.3, paralleling the result of the
real-time RT-PCR. These results demonstrate that adeno-
viral-mediated overexpression of 5BSL3.1 and 5BSL3.2
could efficiently inhibit HCV replication in cultured cells.Discussion
The SL structures in the NS5B coding region were
recently demonstrated to function as CRE, and moreover the
mutation in SL domain which abrogated its binding to RdRp
has also been found to abolish the replication ability of
replicon, suggesting that HCV RNA replication likely
involves physical interaction between RdRp and SL domain
containing CRE. Whether binding directly or indirectly via
other viral and/or cellular component of replication com-
plex, it is reasonable to assume that overexpression of RNA
species mimicking the SL structures could act as decoy to
sequester the replication complex containing RdRp, thereby
inhibiting HCV replication. The data presented here support
this hypothesis by showing that both in vitro transcribed
RNAs and pol III-directed transcripts corresponding to
5BSL3.1 and 5BSL3.2 efficiently inhibited HCV replicon-
encoded luciferase expression, and moreover, coupled
with recombinant adenovirus delivery, overexpression ofFig. 4. Correlation between NS5B-binding ability and anti-HCV activity of
mutant 5BSL3.2. (A) The sequence and secondary structure of wild- and
two mutant-type 5BSL3.2. Nucleotide alterations are indicated by boxes.
(B) Huh-7 cells were transfected with linearized pLMH14, pAM8-1, and
pShuttle empty or pShuttleSL vector. Relative luciferase activities in the
lysates were determined at 72 h posttransfection. The columns and bars
represent the means and standard deviations of three independent triplicate
transfections. (C) Gel shift analysis of the NS5B-binding ability of 5BSL3.2
RNA. Labeled NS5B RNA was incubated with cytoplasmic lysate from
HepG2 cells expressing myc-tagged NS5B protein alone or in the presence
of 25- or 200-fold molar excess of unlabeled homologous NS5B RNA,
wild-, or mutant-type 5BSL3.2 RNA. The reaction mixtures were left alone
or further incubated with mAb against the myc-epitope. The final reaction
mixtures were analyzed by electrophoresis on a non-denaturing polyacry-
lamide gel. Shifted and supershifted complexes are indicated by single and
double asterisks, respectively.
Fig. 5. Dose-dependent inhibition of HCV replication by adenoviral-
mediated expression of 5BSL3.1 and 5BSL3.2 RNA. Huh-NNRZ cells
were mock infected or infected with each AdSLRNA at the MOI of 10, 25,
and 50. (A) After a 5-day culture in the absence of G418 selection, the
transduced cells were harvested and HCV replicon RNAs were quantified
with real-time RT-PCR. (B) Following a 10-day culture either in the
absence (grey columns) or presence (black columns) of G418 selection, the
viable cells were quantified. Representative data are from three separate
experiments.
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replication, as evidenced by significant reduction in HCV
transcripts (by 35- and 38-fold, respectively) and marked
decrease in viable cell count (by 18- and 20-fold,
respectively) in the G418 selection assay.
Overexpression of SL RNAs to prevent the binding of
RdRp to its physiological target represents a novel anti-
HCV approach with obvious advantage. Distinct from
sequence-specific anti-HCV molecules, such as antisense
RNA and siRNA, the efficacy of SL RNA approach
targeting RNA–protein interaction should be less affected
by the extensive variability encountered among HCVisolates. Indeed, SL RNAs derived from HCV 2a, an
evolutionarily distant genotype, were also found to inhibit
the replication of HCV 1b replicon used here in spite of the
genetic heterogeneity between them (Fig. 1). Moreover,
since SL RNA–RdRp interaction is essential for RdRp-
catalyzed HCV RNA replication, any mutation in the NS5B
gene that blocks its binding to the SL RNA also blocks its
binding to the SL sequence in viral RNA. To circumvent SL
RNA-mediated inhibition, double mutation, one in NS5B
and another compensatory one in the SL sequence, is
simultaneously required, thus making the chance of
generation of escape mutants much lower. Additionally,
since the SL RNA molecule is a part of the viral genome, if
administered to patients harboring HCV RNA, it would not
give rise to immune response, which is problematic in other
‘‘intracellular immunization’’ strategies such as dominant-
negative mutants and antisense RNA (Dove, 2002).
Among the SL structures studied here, both 5BSL3.1 and
5BSL3.2 RNAwere found to strongly inhibit the replication
of HCV replicon, which is compatible with that reported by
Lee and coworkers, who determined two SL structures
(designated SL-VI and SL-V, which correspond to 5BSL3.1
and 5BSL3.2, respectively) that are essential for HCV
replication (Lee et al., 2004). The mutagenesis data reported
by You et al. and later by Friebe et al., however, showed that
mutational disruption of 5BSL3.2 blocked RNA replication
but no significant phenotypic alteration was observed by
mutation of 5BSL3.1, thus they concluded that only
5BSL3.2 out of all SL structures predicted in NS5B coding
region is indispensable for HCV replication (Friebe et al.,
2005; You et al., 2004). This discordance may be partially
attributable to the fact that because the SL elements reside in
NS5B coding sequence and mutations disrupting SL
structures in most cases would change the amino acid
sequence of NS5B, and the mutational analyses conducted
in those studies were largely limited to preserve the amino
acid sequence of the NS5B protein. Alternatively, the
association of 5BSL3.1 with RdRp, and more likely with
cellular cofactors (see below) may be relatively robust, with
less sequence dependence. Based on the finding that HCV
2a-derived 5BSL3.1 also efficiently inhibited HCV 1b
replicon despite the nucleotide dissimilarities, together with
the fact that most of the nucleotide substitutions in 5BSL3.1
from HCV 2a are compensatory base pair changes, it is
suggested that the SL structure of 5BSL3.1 rather than the
primary sequence my be important for its function. Addi-
tionally, it was recently reported that kissing-loop inter-
action between the upper loop sequence of 5BSL3.2 and
that of the SL2 in the X-tail is essential for HCV replication
(Friebe et al., 2005). If so, 5BSL3.2 element is more likely
to function as the part of the pseudoknot formed by
interacting with the complementary sequence in SL2 of
the X-tail. The data presented here show that 5BSL3.2 RNA
can act as a potent decoy independently, and moreover the
ability of 5BSL3.2 to inhibit the replication of HCV replicon
was not significantly affected by introduction of two A to U
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presumed kissing-loop interaction. These results largely
lessen, if could not rule out completely, the possibility that
SL RNA acts by interfering RNA–RNA kissing interaction.
In view of the observation that inhibition of HCV
replication always correlated with the expression of the
RNA corresponding to 5BSL3.1 or 5BSL3.2, and mutant
SL RNAs with debilitated protein-binding activity were
also unable to inhibit HCV replication (Fig. 4), it is
suggested that HCV replication was inhibited in SL RNA
expressing cells because RdRp-catalyzed RNA synthesis
was competitively squelched by the presence of excess of
SL RNA which sequestered the component(s) of replicase
complex. In addition to RdRp, the SL RNAs could
potentially function by competing with the viral nascent
transcript for association with cellular factors involved in
HCV RNA replication. In fact, multiple proteins have been
suggested to be associated with the formation of the
replication complex, such as polypyrimidine tract-binding
protein (Tsuchihara et al., 1997), autoantigen La (Spangberg
et al., 1999), and human VAMP-associated protein, a
SNARE-like protein (Gao et al., 2004). The possibility that
cellular factors associate with SL domain may bring the
safety of SL RNA-based approach into question. As judged
by morphologic observation and viability measurement
(Fig. 5B), however, no discernible adverse effects was
found in Huh-NNRZ cells expressing SL-containing tran-
scripts, thereby reducing the concern that overexpression of
SL RNA may sequester essential cellular factors and be
consequently deleterious to cell viability and cell function.
Nevertheless, further studies are required to determine
whether the SL RNA-based inhibition strategy is limited
by its sequestration of essential cellular factors. If this is the
case, it is necessary to engineer altered SL RNA with
diminished ability to bind cellular factors but retaining the
capability to inhibit HCV replication.
In this study, we have shown that expression of small
RNAs corresponding to 5BSL3.1 and 5BSL3.2 in trans can
efficiently inhibit HCV replication, which suggests that use
of SL RNA decoys is a promising new stratagem for
combating HCV infection. Further studies are required to
determine the range and duration of SL RNA-mediated
inhibition for natural HCV isolates and to explore the
feasibility of combining the therapeutic SL RNAs with other
modalities to obtain additive or synergistic anti-HCV effect.
Additionally, the use of SL RNAs also represents a novel
and complementary approach to investigate the molecular
mechanism of HCV RNA replication.Materials and methods
Plasmids
The pShuttleU6 was created as previously described
(Zhang et al., 2004). pGEMEX-1 vector (Promega) wasmodified by deletion of all of the T7 gene 10 and
introduction of BamHI and EcoRI sites between T7
promoter and T7 terminator (Zhang et al., 1999). Sense
and antisense oligonucleotides of SL-coding sequence plus
5 thymidines, which contain cohesive ends for BamHI and
EcoRI at the 5V- and 3V-ends, were synthesized and annealed
by heating at 95 -C for 10 min and slowly cooled down to
room temperature. After a gel electrophoresis purification,
these annealed oligonucleotides were inserted into the
BamHI and EcoRI sites of pShuttleU6 and modified
pGEMEX, creating pShuttleSL and pGEMEXSL vectors,
respectively. The sequences of these constructs were
confirmed by nucleotide sequencing.
Adenovirus
Each expression cassette in pShuttleSL, which is flan-
ked by I-CeuI and PI-SceI sites, was digested with these
two restriction enzymes, and ligated to the E1- and E3-
deleted Adeno-X viral DNA (I-CeuI and PI-SceI digested)
(Adeno-X Expression System, Clontech). The resultant
adenoviral DNAs were digested with PacI and then
transfected into low-passage 293 cells. Seven days follow-
ing transfection, crude virus was prepared from the
transfected cells by three cycles of freeze–thawing, and
further amplified in 293 cells by several rounds of
infection. The purified virus was aliquoted and stored at
80 -C before use. The authenticity of recombinant
adenoviral DNAs was verified before preparing high-titer
viral stocks.
Cells
The cell lines Huh-7 and 293 were purchased from the
American Type Culture Collection (ATCC) and maintained
in Dulbecco’s modified Eagle’s medium (DMEM, Invitro-
gen) supplemented with 10% fetal calf serum and 50 u/ml
penicillin and streptomycin in a 5% CO2 humidified
atmosphere. A Huh-7-derived cell line (Huh-NNRZ) stably
replicating HCV subgenomic replicon was grown in
DMEM medium containing 300 Ag/ml G418 (Geneticin,
Invitrogen).
In vitro transcription
pGEMEXSL plasmids were linearized by digestion with
EcoRI, and then transcribed in vitro using T7 RNA
polymerase according to the protocol supplied by the
manufacturer (Roche). For transcription of replicon RNA,
pLMH14 was linearized at XbaI site located immediately
downstream of the HDV ribozyme, and the fragment was
used as the template for run-off RNA synthesis. After
transcription, 10 U of RQ DNaseI (Promega) were added to
the reaction mixture to digest DNA templates. The mixture
was extracted with phenol–chloroform and RNA was
precipitated with ethanol–7.5 M ammonium acetate.
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Huh-7 cells were seeded onto 6- or 12-well plates 24 h
before transfection. Two microgram of each pShuttleSL,
0.5 Ag of XbaI-linearized pLMH14, pLMH14GHD,
pHCVRLNS5B, or pEMCVRLNS5B, 0.5 Ag of pAM8-1,
and 0.1 Ag of pRL-TK vector were cotransfected into cells
with TransFast Transfection Reagent (Promega). For RNA
transfection, 2 Ag of each in vitro transcribed SL RNA and 1
Ag of replicon RNA in vitro transcribed from pLMH14 or
pLMH14GHD were cotransfected into Huh-7 cells with
Lipofectin Reagent (Invitrogen). The cells were harvested at
the indicated time points, and cell lysates were assayed for
luciferase activity as described below.
Luciferase assay
Cell lysates were prepared from transfected cells,
centrifuged briefly, and 20 Al of the supernatants was used
for luciferase assays with Dual-Luciferase Reporter Assay
System (Promega) according to the manufacturer’s instruc-
tions. Luciferase activities were measured using a TD-20/20
Luminometer (Promega).
Gel mobility shift assay
NS5B RNA (nt 9067–9374) probe was synthesized by in
vitro transcription as described above. Cytoplasmic lysate
was prepared from HepG2 cells expressing myc-tagged
NS5B protein and incubated with labeled RNA probe at
room temperature for 30 min in a buffer containing 10 mM
HEPES (pH 7.6), 40 mM KCl, 3 mM MgCl2, 2 mM
dithiothreitol, 10% glycerol, and 200 Ag/ml yeast RNA. To
perform gel mobility supershift analysis, following RNA–
protein binding, 3 Al of a mAb against myc-tag (9E10,
Santacruz) was added and further incubated at room
temperature for 30 min. For competition assay, a 25- or
200-fold molar excess of unlabeled homologous NS5B
RNA, wild-, or mutant-type 5BSL3.2 was added. The final
reaction mixture was resolved by electrophoresis on a non-
denaturing polyacrylamide gel.
Real-time RT-PCR
RNAs were isolated from cultured cells with Trizol
reagent (Invitrogen) and treated with RNase-free DNase
(Promega). One microgram of DNase-treated total RNAwas
reverse transcribed using a primer complementary to NS5B
5V-ACGGAGCGGATGTGGTTGAC-3V. After incubation at
95 -C for 5 min, the resulting cDNA was quantified with
SYBR GREEN according to the protocol supplied by the
manufacturer (Takara). PCR was performed with a primer
5V- TGGTCTACGCCACAACATCC-3V and the primer used
in RT reaction. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA level in each sample was simultaneously
quantified to normalize the value of HCV replicon RNA.G418 selection assay
Huh-NNRZ cells were mock infected or infected with
each AdSLRNA. Twenty-four hours later, the medium was
changed with fresh DMEM containing 0 or 300 Ag/ml
G418. After an additional 10-day culture, cell viability was
measured with cell proliferation reagent WST-1 (Roche)
according to the manufacturer’s instructions.References
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